Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-03-22

Clinical Trial Update: Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reports safety and bioactivity data for AXT107 in diabetic macular edema, with the study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AXT107

Snippet

Sponsor: AsclepiX Therapeutics, Inc. | Conditions: Diabetic Macular Edema (DME) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-03-22